AstraZeneca is a global biopharmaceutical company that researches, develops, and commercializes prescription medicines. The company operates across three main therapy areas: Oncology, BioPharmaceuticals, and Rare Disease. It serves patients worldwide through a broad-based global network, focusing on primary care, specialty care, and rare diseases. Key subsidiaries include Alexion, MedImmune, and Cambridge Antibody Technology. The company was formed in 1999 through the merger of Sweden's Astra AB and the UK's Zeneca Group PLC. Notable partnerships include agreements with Daiichi Sankyo for cancer medicines and the University of Oxford for vaccine development. AstraZeneca also launched Evinova, a health-tech business, and maintains strategic R&D centers in locations such as Beijing, Shanghai, Cambridge, and Gaithersburg.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Drug Manufacturers - General Homepage astrazeneca.com
Sector Healthcare IR page astrazeneca.com/investor-relations.html
Tags
oncology, biopharmaceuticals, rare disease, cardiovascular, respiratory, immunology, infectious disease, cell therapies, vaccines, prescription medicines, Alexion, MedImmune, Cambridge Antibody Technology, Evinova, KuDOS Pharmaceuticals, Astra AB, Zeneca Group PLC
Press page —

Metrics

Valuation  
Market cap £ 187.717B
Market cap (USD) $ 247.623B
P/E 24.75
PEG 0.54
P/BV 5.03
P/S 4.31
P/OCF 17.38
P/FCF 21.53
Dividend yield —
Turnover / mcap —
Returns  
ROE 22.8%
ROI 13.9%
ROIC 15.4%
Profit margin 17.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 46.0%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 50.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 363
Quality score 44.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011
Revenue 58.739B 54.073B 45.811B 44.351B 37.417B 26.617B 24.384B 22.09B 22.465B — — 26.095B 25.711B 27.973B 33.591B
Net profit 10.233B 7.041B 5.961B 3.293B 115M 3.144B 1.227B 2.05B 2.868B — — 1.235B 2.571B 6.327B 10.016B
Free cash flow 11.765B 9.937B 8.984B 8.717B 4.872B 3.838B — — — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011
Share price 182.13 132.61 129.01 — 113.39 — — — — — — — — — —
Price performance 12m 0.32 0 — — — — — — — — — — — — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 5.76B 7.02B 9.64B 10.5B 12.1B 13B 15.2B
↳ YoY growth +21.9% +37.3% +9.1% +15.3% +7.0% +17.0%
↳ 5y CAGR +17.6% +16.7%
Borrowings, current (USD) 1.82B 2.19B 1.66B 5.31B 5.13B 2.34B 3.1B
Borrowings, non-current (USD) 15.7B 17.5B 28.1B 23B 22.4B 26.5B 24.7B
Lease liabilities (USD) 675M 681M 987M 953M 1.13B 1.45B 1.8B
Cash and deposits (USD) 5.37B 7.83B 6.33B 6.17B 5.84B 5.49B 5.71B
Intangible assets (USD) 20.8B 20.9B 42.4B 39.3B 38.1B 37.2B 37.8B
Right-of-use assets (USD) 647M 666M 988M 942M 1.1B 1.4B 1.74B
Net debt (borrowings + leases - cash) (USD) 12.9B 12.5B 24.5B 23.1B 22.8B 24.8B 23.9B
Cash flow detail
Operating cash flow (USD) 2.97B 4.8B 5.96B 9.81B 10.3B 11.9B 14.6B
Purchases of property, plant and equipment (USD) -979M -961M -1.09B -1.09B -1.36B -1.92B -2.81B
Purchases of intangible assets (USD) -1.48B -1.65B -1.11B -1.48B -2.42B -2.66B -3.1B
Change in receivables (cash effect) (USD) -898M -739M -961M -1.35B -1.43B -1.62B -1.73B
Change in inventories (cash effect) (USD) -316M -621M 1.58B 3.94B -669M -131M -755M
Dividends paid (cash effect) (USD) -3.59B -3.57B -3.86B -4.36B -4.48B -4.63B -4.97B
Share buybacks (cash effect) (USD) — — — 0.00 0.00 -81M -521M
Interest paid (cash effect) (USD) -774M -733M -721M -849M -1.08B -1.31B -1.32B
Income taxes paid (cash effect) (USD) -1.12B -1.56B -1.74B -1.62B -2.37B -2.75B -2.85B
Operating cash flow before change in receivables (USD) 3.87B 5.54B 6.92B 11.2B 11.8B 13.5B 16.3B
Free cash flow (OCF - PPE - intangibles) (USD) 509M 2.19B 3.76B 7.24B 6.57B 7.28B 8.67B
Income detail
Research and development expense (USD) 6.06B 5.99B 9.74B 9.76B 10.9B 13.6B 14.2B
↳ 5y CAGR +17.5% +18.9%
Total comprehensive income (USD) 616M 4.75B -30M 2.42B 6.69B 6.24B 12.9B
Comprehensive income to owners (USD) 723M 4.8B -33M 2.41B 6.69B 6.24B 12.9B
Reported Feb 22, 2022 Feb 22, 2022 Feb 22, 2022 Feb 18, 2025 Feb 18, 2025 Feb 18, 2025 Feb 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Klygefa (gefurulimab) approved in the EU Bull 5 Bear 0 Clinical/regulatory

Klygefa (gefurulimab) approved in the EU for the treatment of adults with generalised myasthenia gravis (gMG)

Approval based on PREVAIL Phase III trial demonstrating statistically significant and clinically meaningful improvement in Myasthenia Gravis Activities of Daily Living score

First and only approved dual-binding nanobody C5 inhibitor in the EU, offering once-weekly subcutaneous self-administration via autoinjector with rapid and sustained disease control

Alexion, AstraZeneca Rare Disease’s Klygefa (gefurulimab) has been approved in the European Union (EU) as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody positive. Klygefa is the first and only dual-binding nanobody C5 inhibitor, offering once-weekly subcutaneous self-administration via autoinjector.

The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and was based on positive results from the pivotal PREVAIL Phase III trial.

Klygefa (gefurulimab) approved in the US Bull 5 Bear 0 Clinical/regulatory

Klygefa (gefurulimab) approved in the US for the treatment of generalised myasthenia gravis (gMG) in adult patients

Approval supported by PREVAIL Phase III results showing statistically significant and clinically meaningful improvements in activities of daily living starting as early as week one and sustained through one year

First and only approved dual-binding nanobody C5 inhibitor in the US, offering once-weekly subcutaneous self-administration via autoinjector with rapid and sustained disease control

Alexion, AstraZeneca Rare Disease’s Klygefa (gefurulimab) has been approved in the US for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. Klygefa is the first and only dual-binding nanobody C5 inhibitor, offering once-weekly subcutaneous self-administration via autoinjector.

The approval by the US Food and Drug Administration (FDA) was based on positive results from the pivotal PREVAIL Phase III trial.

Imfinzi + EV approved in US in bladder cancer Bull 5 Bear 0 Clinical/regulatory

Perioperative Imfinzi approved in the US in novel regimen with neoadjuvant enfortumab vedotin for patients with muscle-invasive bladder cancer

Based on VOLGA Phase III trial data which showed a 49% reduction in risk of recurrence and a 42% reduction in risk of death, with a manageable safety profile

Approval reinforces potential of Imfinzi as an immunotherapy backbone across muscle-invasive and non-muscle-invasive bladder cancer

AstraZeneca’s Imfinzi (durvalumab) in combination with enfortumab vedotin (EV) as neoadjuvant treatment, followed by Imfinzi monotherapy as adjuvant treatment after radical cystectomy (surgery to remove the bladder), has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or have refused cisplatin-based chemotherapy.

The approval was granted by the Food and Drug Administration after securing Priority Review and was based on results from the VOLGA Phase III trial which were presented during a Presidential Symposium at the 2026 European Society for Medical Oncology (ESMO) Congress and simultaneously published in The New England Journal of Medicine.

Prompts

AstraZeneca (ticker AZN), listed in United Kingdom.

ETFs Holding AstraZeneca

ETF Weight in ETF Shares Market value As of
PGRI 5.84% 2,145 $ 401.42K Jun 30, 2026
MEDX 4.98% 5,015 $ 950.944K Jun 30, 2026
OSEA 4.40% 88,081 $ 16.274M Nov 13, 2026
PRVS 4.19% 7,119 $ 1.15M Sep 30, 2026
TINS 4.08% 1,274 $ 238.419K Jun 30, 2026
AGQI 3.97% 11,077 $ 2.034M Nov 16, 2026
PCIG 3.27% 4,893 $ 914.652K Jun 30, 2026
OZEM 3.27% 10,026 $ 1.827M Nov 17, 2026
IDVO 3.17% 214,874 $ 40.744M Jun 30, 2026
TXUG 3.13% 852 $ 138.135K Aug 31, 2026
JDVI 3.10% 117,601 $ 22.008M Jun 30, 2026
PIEQ 3.05% 216,526 $ 40.497M Jun 30, 2026
HRTS 2.91% 9,969 $ 1.617M Aug 31, 2026
HELX 2.70% 3,979 $ 754.498K Jun 30, 2026
TXUE 2.68% 92,357 $ 14.974M Aug 31, 2026
IDYN 2.64% 15,804 $ 2.924M Nov 16, 2026
EFFI 2.50% 20,468 $ 3.782M Nov 13, 2026
UMMA 2.50% 45,418 $ 7.371M Aug 31, 2026
THOR 2.33% 3,400 $ 551.242K Aug 31, 2026
SWP 2.24% 20,724 $ 3.36M Aug 31, 2026
CGDG 2.23% 723,300 $ 133.792M Nov 16, 2026
DTAN 2.16% 2,577 $ 469.833K Nov 17, 2026
DIVD 2.15% 3,215 $ 590K Nov 18, 2026
PJFV 2.15% 31,456 $ 5.733M Nov 18, 2026
JDVL 2.15% 99,586 $ 18.883M Jun 30, 2026
TOUS 2.13% 198,572 $ 33.686M Jul 31, 2026
GDOC 2.02% 2,440 $ 395.986K Aug 31, 2026
CANC 2.00% 25,983 $ 4.214M Aug 31, 2026
BKCG 1.93% 13,669 $ 2.319M Jul 31, 2026
IVSI 1.93% 816 $ 152.616K Jun 30, 2026
IDVZ 1.81% 20,959 $ 3.555M Jul 31, 2026
PVAL 1.49% 1,298,295 $ 210.493M Aug 31, 2026
ENHI 1.46% 1,667 $ 308.471K Nov 16, 2026
BIDD 1.46% 28,646 $ 5.301M Nov 16, 2026
MTRA 1.46% 11,989 $ 2.036M Jul 31, 2026
FFDI 1.44% 1,637 $ 278.696K Jul 31, 2026
DIHP 1.41% 505,245 $ 93.16M Nov 12, 2026
ILOW 1.39% 159,889 $ 25.948M Aug 31, 2026
YLDE 1.32% 11,254 $ 2.134M Jun 30, 2026
LCTD 1.28% 21,894 $ 4.051M Nov 16, 2026
FBCV 1.25% 13,054 $ 2.214M Jul 31, 2026
CSTK 1.21% 12,577 $ 2.134M Jul 31, 2026
CGIC 1.17% 161,460 $ 29.866M Nov 16, 2026
SPIN 1.17% 2,822 $ 519.304K Nov 16, 2026
NTSI 1.07% 28,368 $ 5.309M Jun 30, 2026
APIE 1.01% 72,470 $ 11.75M Aug 31, 2026
RGEF 1.01% 42,362 $ 7.795M Nov 17, 2026
QUIZ 1.01% 5,762 $ 934.518K Aug 31, 2026
SEIE 0.97% 59,125 $ 11.065M Jun 30, 2026
GINX 0.97% 6,369 $ 1.033M Aug 31, 2026
TGLB 0.94% 1,447 $ 246.15K Jul 31, 2026
RINT 0.89% 6,606 $ 1.236M Jun 30, 2026
CGIE 0.84% 110,172 $ 20.379M Nov 16, 2026
DFAI 0.84% 830,915 $ 153.219M Nov 12, 2026
KNO 0.82% 1,987 $ 371.852K Jun 30, 2026
TIER 0.82% 1,684 $ 286.466K Jul 31, 2026
FENI 0.81% 445,774 $ 83.373M Jun 30, 2026
DFSI 0.81% 51,729 $ 9.538M Nov 12, 2026
FFLV 0.80% 771 $ 130.792K Jul 31, 2026
FFGX 0.72% 2,311 $ 393.443K Jul 31, 2026
NBIE 0.70% 10,835 $ 1.747M Aug 31, 2026
TVAL 0.69% 43,015 $ 7.916M Nov 17, 2026
THMZ 0.67% 1,942 $ 363.43K Jun 30, 2026
JHID 0.66% 385 $ 72.05K Jun 30, 2026
INCE 0.65% 4,314 $ 818.021K Jun 30, 2026
SROI 0.53% 586 $ 99.765K Jul 31, 2026
RCGE 0.53% 2,869 $ 520K Nov 18, 2026
RFDI 0.53% 5,108 $ 869.623K Jul 31, 2026
CGNG 0.52% 82,159 $ 15.197M Nov 16, 2026
GPT 0.51% 636 $ 120.598K Jun 30, 2026
TDI 0.44% 8,535 $ 1.596M Jun 30, 2026
AVDE 0.43% 459,767 $ 84.606M Nov 16, 2026
DFIC 0.42% 354,723 $ 65.405M Nov 12, 2026
RGLO 0.38% 6,859 $ 1.288M Jun 30, 2026
AVSD 0.37% 7,533 $ 1.386M Nov 16, 2026
CORO 0.36% 313,627 $ 58.037M Nov 16, 2026
DXIV 0.29% 3,731 $ 687.929K Nov 12, 2026
WSGE 0.26% 857 $ 156.205K Nov 18, 2026
IQSZ 0.26% 2,657 $ 451.312K Jul 31, 2026
DFAX 0.22% 142,583 $ 26.29M Nov 12, 2026
GEW 0.17% 1,542 $ 250.101K Aug 31, 2026
FTLS 0.14% 19,450 $ 0.00 Nov 16, 2026
IALT short -0.07% -29,978 $ -5.547M Nov 16, 2026
NPFE 0.00% 128 $ 21.714K Jul 31, 2026
EBI 0.00% 12 $ 1,945.56 Aug 31, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
AZN canonical Common share — GB lse 121.03 GBP 2026-09-14
AZN Common share — SE nordic — —
AZN Common share — US nyse 161.47 USD 2026-09-30